Advancing the future of cancer therapeutics 🧬

ALADDIN brings together interdisciplinary expertise to accelerate therapeutic nanobody discovery and validation.

Because innovation in early stages of research can make a real difference in future care. 🔬

aladdin-project.eu/

ALADDIN: Accelerating therapeutic antibody discovery to eradicate cancer ALADDIN (Accelerated Discovery Nanobody Platform) is a research project funded by the European Innovation Council (EIC)'s Pathfinder Open programme. The goal of the project is to develop and bring to the market a platform that improves the generation and identification of therapeutic nanobodies and

Discover ALADDIN in action! 🎬

How can nanobody discovery be made faster, more precise & more efficient?

Our motion graphic presents the ALADDIN approach and objectives. It showcases how we combine diverse disciplines to accelerate nanobody discovery.

▶️ Watch:

A next step toward protection against Ebola viruses 💡

Researchers have developed a bispecific nanobody-based therapeutic capable of neutralising multiple ebolavirus species.

Read more 🔗:

Meet the ALADDIN consortium: International Iberian Nanotechnology Laboratory (INL) YouTube video by ALADDIN project

Next up in our partner video presentations: International Iberian Nanotechnology Laboratory 🎥

In this video, PI Alar Ainla explains the role of #microfluidics in the ALADDIN project and the importance of diverse teams in solving challenges like tackling cancer.

www.youtube.com/watch?v=8jpA...

It's #WorldColorectalCancerDay 🌍

Still one of the most common and deadly cancers worldwide—but early detection, research, and innovation can change outcomes.

In ALADDIN, we study colorectal cancer to advance nanobody discovery and aim to contribute to more effective treatments. 👥

Last week, we had an exciting day of video recordings at the @isciiisalud.bsky.social and Hospital Universitario Fundación Jiménez Díaz (@quironsalud-qs.bsky.social) 📹

We continue soon with our partner video presentations, stay tuned ⏰

#ALADDINproject #EICPathfinder

Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler Communications Biology - The Therapeutic Nanobody Profiler is a tool to characterise developability traits specific to nanobodies to support therapeutic design.

Introducing the Therapeutic Nanobody Profiler 🧬

Optimising developability is key to biotherapeutic design, but tools for antibodies don’t always translate to nanobodies.

This manuscript presents an open-source tool to assess nanobody developability.

Our mission: to develop nanobodies for future cancer therapeutics in a way that is...

📈 More efficient
📍 More precise
🐁 More ethical

...than current options.

Read more: aladdin-project.eu

Meet the ALADDIN consortium: Hebrew University of Jerusalem (HUJI) YouTube video by ALADDIN project

We continue with our video series by presenting the work of @hebrewuniversity.bsky.social 💫

Here, @dinaschneidman.bsky.social describes how ALADDIN accelerates nanobody discovery, and how her team contributes to this mission with #AI & machine learning 🤖

youtu.be/dSvm1XbdvnY

#EICPathfinder

Targeting mGlyR with nanobodies for depression Nature Communications - This report describes a nanobody targeting glycine receptor mGlyR that inhibits its ability to regulate G protein signaling and produces anti-depressant effects in mice...

Nanobody-based therapies have potential for neuropsychiatric disorders 🧠

Researchers developed nanobodies targeting the glycine receptor mGlyR, a key player in depression.

Intranasal delivery produced rapid and lasting antidepressant effects in mice.

ALADDIN: Accelerating therapeutic antibody discovery to eradicate cancer ALADDIN (Accelerated Discovery Nanobody Platform) is a research project funded by the European Innovation Council (EIC)'s Pathfinder Open programme. The goal of the project is to develop and bring to the market a platform that improves the generation and identification of therapeutic nanobodies and

A clear overview of our project? Say no more! 🎬

Discover ALADDIN in motion through our presentation video, where we explain how we tackle the current hurdles of nanobody development with our integrated approach.

Watch the animation in a couple of minutes! ▶️

From inspiration to innovation 🔍

ALADDIN draws inspiration from the humane immune system to support work towards advanced nanobody-based therapies.

Through multidisciplinary collaboration, we reshape how nanobodies are discovered and engineered.

aladdin-project.eu/

#EICPathfinder

Meet the ALADDIN consortium: CNB Meet the ALADDIN consortium through video interviews! In this series, our partners share key insights from the ALADDIN project and highlights of their work. In this video, our project coordinator Luis Ángel Fernández from the Centro Nacional de Biotecnología (CNB-CSIC) in Madrid, Spain, explains h

Meet the ALADDIN consortium through videos💡

We’re excited to present our partners through video interviews.

In this first video, our project coordinator Luis Ángel Fernández from @cnb-csic.bsky.social explains his team’s role and the potential impacts of the project.

Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens Nature Nanotechnology - Engineered mucus-tethering bispecific nanobodies neutralize and entrap viruses to enhance mucosal immunity, preventing influenza infection and limiting SARS-CoV-2 transmission.

This study reports on the engineering of mucus-tethering bispecific nanobodies. 🔬

Results from preclinical models:

🫁 Increased retention in the airways
🐭Enhanced protection against influenza in mice
🐹 Reduced SARS-CoV-2 transmission in hamsters

Curious about ALADDIN, but only have a couple of minutes to spare? 👀

Discover our new motion graphic animation video to quickly learn how our project accelerates the discovery and preclinical validation of nanobodies.

▶️ Watch the video:

Interdisciplinary expertise from across Europe & beyond 🌍

ALADDIN is a joint effort between 8 partner organisations:

@cnb-csic.bsky.social
Hebrew University
@inl.int
@liu.se
@isciiisalud.bsky.social
Instituto Investigación Sanitaria Fundación Jiménez Díaz
InCellia
Zirka InnoTech

Nanobodies targeting ion channels: advancing therapeutics through precision and structural insights Ion channels, which are integral to cellular signaling and homeostasis, are implicated in a variety of diseases, including neurological disorders, cardiovascular conditions, and cancers. Despite their importance, targeting ion channels therapeutically is challenging due to issues such as structural conservat

Ion channels are proteins controlling the flow of specific ions across cell membranes. They are implicated in diseases like cancer. 🔬

Targeting ion channels is challenging, but nanobodies can help, thanks to their precision and adaptability. 💡

Discover more:

Age and generation-based model of metastatic cancer: From micrometastases to macrometastases Metastasis remains the decisive event in most solid cancers, yet the mathematical tools we use to describe it are still largely tied to tumor size. In…

A paper including ALADDIN PI Georgios Lolas from InCELLia as one of the authors 👏

The article presents an age- and generation-based mathematical model to improve the understanding of how metastases evolve. 🔬

Read the full article:

Take a glimpse into ALADDIN 🧞

How can nanobody discovery be made faster, more efficient, and smarter?

Our new motion graphic video introduces the ALADDIN project and its mission to transform the discovery of monoclonal antibodies.

🎥 Dive into our story:

Happy International Day of Women and Girls in Science!

Today, we promote the equal participation of women in STEM. Closing the gender gap is needed for R&I to change the world.

ALADDIN counts on the efforts of brilliant women. We’re excited to present some of them to you! 💎

A new era of nanobody discovery 🚀

ALADDIN brings together multidisciplinary expertise to streamline the process:

🧬 Target identification
🧬 Nanobody discovery & optimisation
🧬 AI-analysis & mathematical modelling
🧬 Preclinical validation in vivo

aladdin-project.eu

Official website of World Cancer Day by UICC | 4 February An international awareness day led by the Union for International Cancer Control (UICC) to raise worldwide attention and inspire action for a cancer-free future.

In ALADDIN, our mission is to accelerate nanobody discovery to eradicate cancer.

We aim to contribute to more effective cancer treatment by developing new nanobodies and a streamlined platform for their discovery.

www.worldcancerday.org/

#UnitedByUnique #WorldCancerDay

Today, on 4 February, we commemorate World Cancer Day.

Cancer affects the lives of millions of people worldwide. Each person has their own unique story. This calls for a people-centred approach to treating cancer—there cannot be a one-size-fits-all solution.

Nanobodies as tools for studying human frataxin biology Communications Biology - Anti-FXN nanobodies (NBs) stabilize FRDA FXN variants in vitro. High-resolution structures of NB-FXN complexes were determined. NBs expressed in human cells localize to the...

Frataxin (FXN) is a protein regulating iron homeostasis, vital for the assembly of iron-sulfur clusters & essential for energy production 🧬

Researchers show nanobodies’ promise as molecular tools for studying FXN function & stability.

Nature Communications Biology:

Big ideas, summarised into a short video ✨

Curious about how ALADDIN is transforming therapeutic antibody discovery? This teaser video gives you a quick look at the project’s goals and cutting-edge approach.

Dive deeper into ALADDIN below!

#EICPathfinder

ALADDIN at a glance:

🔹 Focus: Discovering therapeutic antibodies for cancer
🔹 Challenge: Slow, costly, animal-dependent discovery
🔹 Solution: An integrated platform with cutting-edge technologies, all in one

Read more: aladdin-project.eu

#ALADDINproject #EICPathfinder

How does ALADDIN speed up therapeutic antibody discovery? 🔬

Our motion graphic video walks you through the project’s integrated approach. Take a look!

@cnb-csic.bsky.social @hebrewuniversity.bsky.social @inl.int @liu.se @isciiisalud.bsky.social

#EICPathfinder

🎉 Congratulations to the @projectaladdin.bsky.social!
We are very proud to be coordinating this exciting project. 😊

Discover our approach and vision for advancing cancer research in this new motion graphic video.

Watch it here 👇

#CNB_CSIC @csic.es @csicdivulga.bsky.social

Nanobody therapeutics in autoimmune and immune-mediated inflammatory diseases: experimental insights and translational strategies Nanobodies, single-domain-based VHHs, are antibody fragments derived from heavy-chain-only IgG antibodies found in the Camelidae family that provide m…

Nanobodies offer precise modulation of immune pathways in conditions like rheumatoid arthritis & lupus.

Clinical studies show they effectively target key molecules with promising safety profiles, highlighting their potential for clinical translation. 💎

It's finally here—discover the ALADDIN project through our new motion graphic video! 🎬

Learn about our approach, objectives, and vision for advancing cancer research by watching the full video below! 🧬

#EICPathfinder #ALADDINproject